A Study of SHR6508 in Secondary Hyperparathyroidism
Condition: Secondary Hyperparathyroidism Interventions: Drug: SHR6508; Drug: Cinacalcet Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials